BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.16 HKD | +6.42% |
|
+11.54% | -49.12% |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 | |
| Mar. 22 | Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 19,309 | 4,733 | 783.5 | 783.5 | - |
| Enterprise Value (EV) 1 | 16,477 | 3,555 | 1,025 | -172.8 | -448.3 |
| P/E ratio | -2.83 x | -9.71 x | -8.63 x | -1.65 x | -2.03 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 32.2 x | 3.63 x | - | 4.34 x |
| EV / Revenue | - | 24.2 x | 2.46 x | - | -2.48 x |
| EV / EBITDA | -3.95 x | -6.27 x | -1.75 x | 0.23 x | 0.73 x |
| EV / FCF | -16,102,317 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | 5.78 x | 1.48 x | 0.49 x | 0.37 x | 0.49 x |
| Nbr of stocks (in thousands) | 720,292 | 727,203 | 729,638 | 729,638 | - |
| Reference price 2 | 26.81 | 6.509 | 1.074 | 1.074 | 1.074 |
| Announcement Date | 3/22/22 | 3/24/23 | 3/22/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 147.2 | 416.7 | - | 180.7 |
| EBITDA 1 | - | -4,176 | -567.5 | -584.3 | -735.9 | -615.8 |
| EBIT 1 | - | -703 | -584.5 | -600 | -750.1 | -629 |
| Operating Margin | - | - | -397.09% | -143.97% | - | -348.07% |
| Earnings before Tax (EBT) 1 | - | -4,191 | -489.8 | -184.4 | -644.4 | -527.7 |
| Net income 1 | -1,190 | -4,164 | -484.3 | -174.8 | -527.6 | -460.5 |
| Net margin | - | - | -329.03% | -41.95% | - | -254.86% |
| EPS 2 | -6.220 | -9.480 | -0.6700 | -0.2400 | -0.6500 | -0.5300 |
| Free Cash Flow | - | -1,023 | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 6/30/21 | 3/22/22 | 3/24/23 | 3/22/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 22.83 | 4.193 | 143 | 63.15 | - | - | 353.6 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | - | -347.6 | -136.7 | -189.9 | -370.5 | -391.6 | 15.09 | -121 | -125.3 | -246.3 | -134.6 | -281.3 |
| Net margin | - | -8,289.7% | -95.61% | -300.72% | - | - | 4.27% | - | - | - | - | - |
| EPS 2 | - | -0.4800 | -0.1900 | -0.2600 | -0.5100 | -0.5300 | 0.0200 | -0.1700 | -0.1700 | -0.3400 | -0.1800 | -0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/23/22 | 8/23/22 | 3/24/23 | 8/22/23 | - | - | 3/22/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 2,832 | 1,178 | 486 | 956 | 1,232 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -1,023 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -519% | -14.8% | -5.54% | -25.9% | -27.7% |
| ROA (Net income/ Total Assets) | - | -171% | -13.8% | - | - | - |
| Assets 1 | - | 2,440 | 3,502 | - | - | - |
| Book Value Per Share 2 | - | 4.640 | 4.390 | 4.220 | 2.900 | 2.200 |
| Cash Flow per Share | - | -2.000 | - | - | - | - |
| Capex | - | 1.03 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 6/30/21 | 3/22/22 | 3/24/23 | 3/22/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.074
CNY
Average target price
4.303
CNY
Spread / Average Target
+300.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.12% | 108M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2137 Stock
- Financials Brii Biosciences Limited
